United Therapeutics Corporation
UTHRUnited Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
Drugs in Pipeline
19
Phase 3 Programs
10
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
UTHR Earnings Report
EPS Est: $6.82 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How UTHR's past catalysts played out
UT-15C (treprostinil diolamine)
Pulmonary Arterial Hypertension
Dinutuximab
Small Cell Lung Cancer
Ralinepag
Pulmonary Arterial Hypertension
Oral treprostinil (UT-15C) Sustained Release Tablets
Pulmonary Hypertension
treprostinil diethanolamine
Pulmonary Arterial Hypertension
UT-15
Pulmonary Hypertension
oral treprostinil
PAH
UT-15C SR
Pulmonary Hypertension
Inhaled Treprostinil
Progressive Pulmonary Fibrosis
Treprostinil Diolamine
Pulmonary Arterial Hypertension
0.5% Ivermectin lotion
Pediculosis Capitis
UB-421(25 mg/kg) Q2W
HIV-1 Infection
GGTA1 KO Thymokidney
ESRD (End-Stage Renal Disease)
APD811
Pulmonary Arterial Hypertension
ch14.18 -NCI
Neuroblastoma
10 GE Xenokidney
ESRD (End-Stage Renal Disease)
UT-15C
Pulmonary Hypertension
Tyvaso Inhalation Solution
Pulmonary Arterial Hypertension
UB-421
HIV-1 Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UT-15C (treprostinil diolamine) | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Dinutuximab | Phase 3 | Small Cell Lung Cancer | - | - |
Ralinepag | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Oral treprostinil (UT-15C) Sustained Release Tablets | Phase 3 | Pulmonary Hypertension | - | - |
treprostinil diethanolamine | Phase 3 | Pulmonary Arterial Hypertension | - | - |
UT-15 | Phase 3 | Pulmonary Hypertension | - | - |
oral treprostinil | Phase 3 | PAH | - | - |
UT-15C SR | Phase 3 | Pulmonary Hypertension | - | - |
Inhaled Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis | - | - |
Treprostinil Diolamine | Phase 3 | Pulmonary Arterial Hypertension | - | - |
0.5% Ivermectin lotion | Phase 2 | Pediculosis Capitis | - | - |
UB-421(25 mg/kg) Q2W | Phase 2 | HIV-1 Infection | - | - |
GGTA1 KO Thymokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - | - |
APD811 | Phase 2 | Pulmonary Arterial Hypertension | - | - |
ch14.18 -NCI | Phase 2 | Neuroblastoma | - | - |
10 GE Xenokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - | - |
UT-15C | Phase 2 | Pulmonary Hypertension | - | - |
Tyvaso Inhalation Solution | Phase 2 | Pulmonary Arterial Hypertension | - | - |
UB-421 | Phase 2 | HIV-1 Infection | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in United Therapeutics Corporation's drug pipeline?→
CatalystAlert tracks 19 drug candidates in United Therapeutics Corporation's (UTHR) pipeline across Phase 3, Phase 2. Its lead program is UT-15C (treprostinil diolamine) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is United Therapeutics Corporation's next FDA catalyst?→
United Therapeutics Corporation's (UTHR) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UTHR biotech catalysts?→
Add UTHR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow United Therapeutics Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.